Overview

A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The main objective of this exploratory 8-week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypotheses for a larger randomized-controlled trial with explicit hypotheses and sufficient statistical power.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Buspirone